#22 - Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins

#22 - Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins

0 Calificaciones
0
Episodio
23 of 423
Duración
1H 4min
Idioma
Inglés
Formato
Categoría
Crecimiento personal

In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter's most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part III, Peter and Tom dig into HDL, why "reverse cholesterol transport" is a lot more nuanced than what most of us are taught, lipid transport, apolipoproteins, and more. In addition, this episode highlights the complexity of HDL and a discussion about the CETP inhibitor trials. We discuss: • Reverse cholesterol transport [1:40]; • Lipid transportation, apolipoproteins, VLDL, IDL, and LDL particles [11:00]; • Remnant lipoproteins and apoC-III [16:45]; • Particles having sex: lipid exchange [28:00]; • Cholesteryl Ester Transfer Protein (CETP) and CETP inhibitors [40:45]; • 2006 CETP inhibitor trial: torcetrapib (Pfizer) [54:45]; • 2012 CETP inhibitor trial: dalcetrapib (Hoffmann–La Roche) [56:15]; • 2017 CETP inhibitor trials: evacetrapib (Eli Lilly) and anacetrapib (Merck) [58:00]; and • More. Learn more at www.PeterAttiaMD.com Connect with Peter on Facebook | Twitter | Instagram.


Escucha y lee

Descubre un mundo infinito de historias

  • Lee y escucha todo lo que quieras
  • Más de 1 millón de títulos
  • Títulos exclusivos + Storytel Originals
  • Precio regular: CLP 7,990 al mes
  • Cancela cuando quieras
Suscríbete ahora
Copy of Device Banner Block 894x1036 3
Cover for #22 - Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins

Otros podcasts que te pueden gustar...